



## Publication Presentation Policy Procedures

The DESIR Publication Presentation Policy Procedures (updated in 2023) must be accepted and applied by the investigator in charge of a project endorsed or accepted by the DESIR scientific committee.

These procedures include:

1. Accept that one member of the scientific committee will be the “mentor” of the project. The mentor should be integrated in the project, including the conduct/analysis of the project and the writing of the manuscript, and therefore he/she will be integrated in the list of co-authors. The rank of the mentor in the list of co-authors is the decision of the principal investigator of the project.
2. Refer to the acronym DESIR in the title or the sub-title of any publication. In case the policy of the journal does not accept this, refer to the acronym DESIR in the abstract of the publication.
3. Inform the president of the DESIR scientific committee (and the project mentor) of the status of the project every 6 months (i.e., before each DESIR Scientific Committee meeting) until the publication of the manuscript.
4. Provide the DESIR coordinators with a pdf of the manuscript once published.
5. Acknowledge in the “Acknowledgements section” the DESIR cohort.

Here there are 2 situations:

A/ your study only uses data from DESIR before the 10-year visit (10-year visit not included). The text is then:

*« The DESIR cohort is conducted with Assistance Publique-Hopitaux de Paris (AP-HP, Paris France) as the sponsor. The DESIR cohort (up to 10 years of follow-up) was run with the support of unrestricted grants from Pfizer France. The DESIR cohort is conducted under the control of Assistance publique Hopitaux de Paris via the Clinical Research Unit Paris Centre and under the umbrella of the French Society of Rheumatology and Institut national de la sante et de la recherche medicale (Inserm). Database management was performed within the Department of Epidemiology and Biostatistics (Dr Pascale FABBRO-PERAY, D.I.M., and Nimes, France). We also thank the investigators: Pr Maxime Dougados and Dr Anna Molto (Paris-Cochin), Pr Philippe Dieudé (Paris-Bichat), Pr Laure Gossec (Paris-La Pitie-Salpétriere), Pr Francis Berenbaum (Paris-Saint-*

*Antoine), Pr Pascal Claudepierre (Creteil), Pr Félicie Costantino (Boulogne-Billancourt), Dr Bernadette Saint-Marcoux (Aulnay-sous-Bois), Pr Philippe Goupille (Tours), Dr Emmanuelle Dernis (Le Mans), Pr Clément Prati (Besançon), Pr Cédric Lukas (Montpellier), Pr Véronique Breuil (Nice), Pr Pascal Richette (Paris Lariboisière), Pr Thao Pham (Marseille), Dr Pauline Lasselin (Amiens), Pr Anne Tournadre (Clermont-Ferrand), Dr Nadia Mehzen (Bordeaux), Pr Damien Loeuille (Nancy), Pr Rene-Marc Flipo (Lille), Pr Alain Saraux (Brest), D Stephan Pavy (Le Kremlin-Bicetre), Pr Adeline Ruyszen-Witrand (Toulouse), and Pr Thierry Lequerre (Rouen).*

B/ Your study uses data from the 10 year visit or beyond. The 2023 text is then: « *The DESIR cohort is conducted with Assistance Publique-Hopitaux de Paris (AP-HP, Paris France) as the sponsor and under the umbrella of the French Society of Rheumatology. The DESIR cohort is run with the support of unrestricted grants from (in order of decreasing support) Pfizer France, Biogen, AbbVie, UCB, Lilly, Galapagos, Novartis, MSD, Fresenius and Celltrion HealthCare. We thank the Clinical Research Unit Paris Centre (AP-HP, Paris France), and the Institut national de la sante et de la recherche medicale (Inserm). We also thank the investigators: Pr Maxime Dougados and Dr Anna Molto (Paris-Cochin), Pr Philippe Dieudé (Paris-Bichat), Pr Laure Gossec (Paris-La Pitie-Salpétriere), Pr Francis Berenbaum (Paris-Saint-Antoine), Pr Pascal Claudepierre (Creteil), Pr Félicie Costantino (Boulogne-Billancourt), Dr Bernadette Saint-Marcoux (Aulnay-sous-Bois), Pr Philippe Goupille (Tours), Dr Emmanuelle Dernis (Le Mans), Pr Clément Prati (Besançon), Pr Cédric Lukas (Montpellier), Pr Véronique Breuil (Nice), Pr Pascal Richette (Paris Lariboisière), Pr Thao Pham (Marseille), Dr Pauline Lasselin (Amiens), Pr Anne Tournadre (Clermont-Ferrand), Dr Nadia Mehzen (Bordeaux), Pr Damien Loeuille (Nancy), Pr Rene-Marc Flipo (Lille), Pr Alain Saraux (Brest), D Stephan Pavy (Le Kremlin-Bicetre), Pr Adeline Ruyszen-Witrand (Toulouse), and Pr Thierry Lequerre (Rouen).*

6. Acknowledge in the manuscript (Section Methods) in case of specific use of the biological centralized material "The biological resources center (Paris, Bichat Hospital Claude Bernard – CRB BCB, Certificate number 34457, S. Tubiana) was in charge of centralizing and managing biological data collection". And in that case in the acknowledgments please add: "*We thank the Biological Resource Center of Bichat Hospital (Paris France).*"
7. Insert in the reference list the manuscript which describes the methodology and the main baseline characteristics of the patients (Dougados et al, Joint Bone Spine 2015).
8. Concerning the presentation policy procedure, it is highly recommended
  - to insert the logo of DESIR in any poster presenting data from DESIR,
  - to use the DESIR or DESIR>10 title slide and the DESIR overall background slide in any oral presentation of the project
  - in case of data used at 10 years of follow-up or more, to use the thank you/partners and supports slide provided by the DESIR>10 principal investigator (Laure Gossec)

Paris, 31/01/2023

9. The ClinicalTrials.gov ID NCT01648907 should be mentioned in the manuscript.